Response to Expression of Concern Regarding VIGOR Study
- 16 March 2006
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (11), 1196-1199
- https://doi.org/10.1056/nejmc066096
Abstract
We, the non-Merck authors of the VIGOR study,1 welcome the opportunity to respond to your recent expression of concern2 regarding the VIGOR study. No Merck employee or representative was involved in the drafting of this response. Our evaluation leads us to conclude that our original article followed appropriate clinical trial principles and does not require a correction. Three basic assertions were made in the expression of concern, and we would like to address these assertions point by point.Keywords
This publication has 2 references indexed in Scilit:
- Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.New England Journal of Medicine, 2005
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000